HIV感染女性高危型HPV与宫颈病变1年持续与清除情况
该研究在博茨瓦纳HIV治疗中心纳入300名HIV感染女性,采用高危型HPV检测进行宫颈癌筛查并在1年后随访,237人(79%)完成随访。高危型HPV阳性率从基线28%降至1年时20%(P=0.02),持续率46%、清除率54%、新发率9%;基线HPV阳性且低于CIN2者中40%在随访时进展为CIN2及以上。结论提示HIV感染女性高危型HPV感染进展为宫颈病变的比例较高,以高危型HPV检测延长筛查间隔需谨慎。
要点
- HIV感染女性高危型HPV 1年持续率46%、清除率54%、新发率9%
- 基线HPV阳性且低于CIN2者中40%随访进展为CIN2及以上
- 高危型HPV检测用于HIV感染女性筛查间隔需谨慎,进展与持续常见
核心结论
- HIV感染女性接受一轮高危型HPV筛查与治疗后,高危型HPV及高级别宫颈病变新发率高,从高危型HPV感染进展为宫颈病变的速度值得关注,持续病变常见。
- 以高危型HPV检测延长HIV感染女性的宫颈癌筛查间隔需谨慎。
研究设计与样本
- 前瞻性队列研究,地点为博茨瓦纳的HIV治疗中心,对象为HIV感染女性。
- 基线筛查300人,1年随访时237人完成随访(79%)。
- 采用高危型HPV检测进行宫颈癌筛查并在基线与1年时行分诊评估,按指征提供切除性治疗,以组织病理学为参考标准。
主要发现
- 高危型HPV阳性率从基线28%降至1年时20%(P=0.02)。
- 高危型HPV持续率为46%,清除率为54%,新发率为9%。
- CIN2及以上在发生新发高危型HPV者中最常见(53%),在持续高危型HPV者为32%,在已清除高危型HPV者中亦达30%。
- 基线高危型HPV阳性且低于CIN2的参与者中,40%在随访时进展为CIN2及以上。
临床怎么用
- 对HIV感染女性采用高危型HPV检测筛查后,不宜简单延长筛查间隔,应关注持续感染与病变进展。
- 筛查后应按指征进行分诊评估与切除性治疗,并在1年内重视随访以发现持续或进展病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate 1-year outcomes of cervical cancer screening and treatment using primary high-risk human papillomavirus (HPV) testing in women living with human immunodeficiency virus (HIV). DESIGN: Prospective cohort study. SETTING: HIV treatment centre in Botswana. POPULATION: Women living with HIV. METHODS: Participants underwent cervical cancer screening with high-risk HPV testing and triage evaluation at baseline and 1-year follow up. Excisional treatment was offered as indicated. Histopathology was the reference standard. MAIN OUTCOME MEASURES: Persistence, clearance and incidence of high-risk HPV infection; and persistence, progression, regression, cure and incidence of cervical dysplasia. RESULTS: Among 300 women screened at baseline, 237 attended follow up (79%). High-risk HPV positivity significantly decreased from 28% at baseline to 20% at 1 year (P = 0.02). High-risk HPV persistence was 46% and clearance was 54%; incidence was high at 9%. Prevalence of cervical intraepithelial neoplasia Grade 2 (CIN2) or higher was most common in participants with incident high-risk HPV (53%). CIN2 or higher was also common in those with persistent high-risk HPV (32%) and even in those who cleared high-risk HPV (30%). Of the high-risk HPV-positive participants at baseline with <CIN2, 40% progressed to CIN2 or higher at follow up. CONCLUSION: The high incidence of high-risk HPV and high-grade cervical dysplasia in women living with HIV after one round of high-risk HPV-based screening and treatment raises concern about the rate of progression of high-risk HPV infection to dysplasia. Persistent disease is common. Caution in spacing cervical cancer screening intervals using high-risk HPV testing in women living with HIV is warranted. TWEETABLE ABSTRACT: High incidence and persistence of HPV and CIN2+ in women living with HIV 1 year after screening and treatment.
引用
- Luckett R, Painter H, Hacker MR, et al. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study. BJOG. 2021. PMID: 34008294. doi:10.1111/1471-0528.16758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。